The results of these bioavailability studies indicate that the test formulation of losartan/hydrochlorothiazide 50 + 12.5 mg ( EPR0001 ) tablets is bioequivalent to marketed Preminent reference formulation in Asian Indian and Japanese volunteers , when administered under fasting conditions .